A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

Summary

The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade exposure, and correlate the findings to clinical outcome. This approach will allow to generate new hypotheses regarding mechanism of action of ICI and (primary) resistance mechanisms. The long-term goal is that these novel mechanistic insights will be translated to a clinical setting to develop better biomarkers of ICI efficacy. Importantly, since the investigators will also sequentially profile the immune composition of peripheral blood, this research offers an opportunity to develop circulating (non-invasive) biomarkers. A second aim is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from these ICI-treated cancer patients if they would develop ICI-pneumonitis. These mechanistic insights can directly lead to putative diagnostic biomarkers and therpeutic targets. Since single-cell profiling of blood samples will also be performed, circulating biomarkers of ICI toxicity can also be identified, making non-invasive diagnosis feasible.

Eligibility

Inclusion criteria:

* Adult M/F/X (\>= 18 years)
* Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)
* Patients receiving first-line treatment per guidelines
* Not included in other clinical trials
* Signed informed consent form

Exclusion criteria:

• Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.

Conditions5

Interventions2

Related trials

• Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma — Fudan University
• Biomarkers in Immunotherapy of Melanoma — Institute of Oncology Ljubljana
• Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer — Hunan Province Tumor Hospital
• Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer — Shanghai Chest Hospital
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPC — Sun Yat-sen University
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI — Peking Union Medical College Hospital
• Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer — ETOP IBCSG Partners Foundation

Browse More Trials